The acquisition expands Medtronic’s portfolio of solutions for dealing with difficult airways and addresses the preventable issue of respiratory compromise, which consists of respiratory insufficiency, failure and arrest, dramatically increases the likelihood of adverse outcomes and cost of patient care.
“Aircraft Medical’s offerings complement our portfolio, helping us further our commitment to reducing incidents and potential complications from respiratory compromise globally. The company’s laryngoscopes will play an important role in our airways portfolio as we develop and provide meaningful innovations that improve patient outcomes,” said Steve Blazejewski, senior vice president and president of the Patient Monitoring & Recovery business, Minimally Invasive Therapies Group at Medtronic.
“We are pleased to be joining the Medtronic team as we strive to provide the McGrath® video laryngoscope platform to many more patients around the world,” said Matt McGrath, founder and CEO of Aircraft Medical.
The transaction is expected to meet Medtronic’s long-term financial metrics for acquisitions. Medtronic expects the net impact from this transaction to be earnings neutral in fiscal year 2016 and neutral to accretive to earnings thereafter. Medtronic will report revenue from the Aircraft Medical product line as part of its Patient Monitoring & Recovery division within the Minimally Invasive Therapies Group.
To see the full press release. click here.
